Cardiovascular disease is the major cause of morbidity and mortality in non-insulin dependent diabetes (NIDDM). Age-adjusted mortality is increased some 2-3-fold compared with the non-diabetic population. It accounts for between 50 and 75% of deaths'. The causes of this are not yet completely understood. Control of hyperglycaemia itself has so far had little impact on the incidence of cardiovascular disease. In the general population, smoking, hypertension, raised total and low density lipoprotein (LDL) cholesterol, low high density lipoprotein (HDL) cholesterol and probably raised serum triglyceride have all emerged as risk factors for cardiovascular disease. These also appear to be important in NIDDM. In cross-sectional studies, serum triglyceride, total and LDL cholesterol, low HDL cholesterol and apoprotein Al have been associated with cardiovascular disease in NIDDM2-4. The most common metabolic abnormalities in NIDDM are raised serum triglyceride and low HDL cholesterol. These changes are more pronounced in women who tend to have a greater increase in serum triglyceride and reduction in HDL cholesterol than their non-diabetic counterparts in comparison with men", This may help to explain the relatively greater risk of developing cardiovascular disease in diabetic women than men", From prospective studies, serum triglyceride has emerged as an important risk factor in both sexes", In women low HDL cholesterol" and in middle aged diabetic men serum cholesterol have emerged as important predictors of cardiovascular disease". What effect does standard treatment have on these abnormalities?
Diet has remained the cornerstone of treatment for NIDDM. In the overweight, weight reduction reduces serum triglyceride and raises HDL cholesterol'', In the non-obese, diet may lower serum triglyceride but has little effect on HDL cholesterol", Current practice is to encourage a high fibre, high carbohydrate low saturated fat diet. The beneficial effect of this diet for blood glucose control and improvement in serum lipids may well depend partly on the soluble fibre content. The pharmacological addition of soluble or viscous fibre in the form of guar gum has also been shown to lower total and LDL cholesterol in NIDDMlO. However, the quantity of fibre recommended in some diets is not acceptable to many patients. Indeed, some high carbohydrate diets have been shown to increase serum triglycerides, lower HDL cholesterol and worsen glucose control in NIDDMll. Controversy therefore exists as to which constituent should replace the reduced saturated fat intake which is considered desirable. There is some evidence that partial replacement of complex carbohydrate with mono-unsaturated fat improves glucose control, improves serum triglyceride and HDL cholesterol without raising LDL cholesterol's. The current enthusiasm for high carbohydrate diets in NIDDM may need slight modification. Longer term studies are needed to define what is the optimal diet for people with NIDDM.
When diet alone is not successful in controlling hyperglycaemia, oral hypoglycaemic drugs are used. The sulphonylureas came under a cloud when the American University Group Diabetes Program Study (1970) showed increased cardiovascular mortality in NIDDM in those given tolbutamide when compared with those given diet or insulin. Although the findings of this study were later disputed, the effects of sulphonylureas on serum lipids were investigated. Early cross sectional studies indicated that those on sulphonylureas had lower HDL cholesterol than those on diet or insulin'", Subsequent prospective studies have shown neutral or even beneficial effects of sulphonylureas on serum lipids and lipoproteins-v-", Sulphonylureas probably have little effect on serum lipids, but they do not correct the low HDL cholesterol which is so common in NIDDM and which may be the most important metabolic defect in relation to the pathogenesis of cardiovascular disease. Metformin, the only biguanide drug in common use in the UK, has been shown to have a small effect in lowering total and LDL cholesterol", and serum triglyceride in those with serum cholesterol of more than 6.5 mmol/l-P.
Insulin therapy in NIDDM may improve all lipid fractions in NIDDM, though not necessarily raise HDL cholesterol. Clearly insulin therapy has its own disadvantages and dangers and is not likely to be applicable to the majority of patients.
Hypertension adds significantly to the risk of cardiovascular disease in NIDDM. The prevalence of hypertension is increased in NIDDM, and it appears to exaggerate the existing lipid abnormalities. Serum triglyceride, cholesterol, LDL cholesterol were significantly higher, and the ratio of HDL to LDL cholesterol significantly lower in hypertensive compared to normotensive patients with NIDDMl7. It is not clear whether this is due to hypertension per se or the effect of anti-hypertensive drugs. Certainly many diuretics may increase serum cholesterol and triglyceride, while beta-blockers may increase serum triglyceride and lower HDL cholesterol. In a group of patients with NIDDM and hypertension, those on beta-blockers had higher serum triglyceride and 0141-0768/91/ 070393-021$02.00/0 © 1991 The Royal Society of Medicine significantly lower HDL cholesterol than those on other agents'", Calcium antagonists and angiotensin converting enzyme inhibitors appear not to affect serum lipids. Alpha blockers may even slightly improve the lipid profile in NIDDM19. It would seem sensible where possible to use antihypertensive drugs which do not adversely affect serum lipids in NIDDM.
There remains therefore a large number of patients with NIDDM who have modestly elevated serum triglyceride and low HDL cholesterol concentrations despite diet and oral hypoglycaemic therapy. In the general population these abnormalities would not be thought likely to warrant drug therapy. Does this apply in NIDDM? In the Helsinki Heart Study, middle aged men with mild hyperlipidaemia similar to that seen in NIDDM, recruited from population screening, were randomized to receive the fibrate drug, gemfibrozil or placebo. Those receiving gemfibrozil showed reduced incidence of coronary heart disease compared to those receiving placebo over 5 years-", In NIDDM, another fibrate drug bezafibrate has been shown to lower triglyceride, cholesterol and raise HDL cholesterol over a 4-month periods, The fibrate drugs, with their main effects in reducing triglyceride and increasing HDL cholesterol, together with a modest but variable reduction in serum cholesterol would seem ideally suited to correcting the lipid abnormalities of NIDDM.
The treatment of hypercholesterolaemia, in general, has been revolutionized with the advent of the HMG Co A reductase inhibitors. Although raised serum and LDL cholesterol are not the main problem in NIDDM, one such drug lovastatin, has been shown to reduce both serum cholesterol and triglyceride in NIDDM, though without much effect on HDL cholesterol!'. It could be argued that this reduction in serum triglyceride together with near normalization ofLDL cholesterol concentration could be as beneficial as the effects seen with the fibrates in NIDDM. There are as yet no long-term studies with lipid lowering drugs in patients with NIDDM. There is a clear need for long-term prospective studies ill people with NIDDM to ascertain whether by correcting the accompanying lipid abnormalities by drug therapy, the progress of cardiovascular disease can be slowed down and its mortality reduced.
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